Glenmark Pharmaceuticals Limited · NSE: GLENMARK · BSE: 532296
Glenmark Pharmaceuticals
Quarterly results as filed with BSE. Latest: Q1 FY27 (Apr–Jun 2026), filed 31 Jul 2026.
Q1 FY27 · Consolidated
Revenue
4,018.48₹ Cr
+23.1% vs year ago
Net profit
482.83₹ Cr
+927.9% vs year ago
EPS, basic
17.11₹
+930.7% vs year ago
Net margin
12.0%
+10.6 pts vs year ago
Quarter by quarter
| Quarter | Revenue | YoY | Net profit | YoY | EPS (₹) | Filed |
|---|---|---|---|---|---|---|
| Q1 FY27Apr–Jun 2026 | 4,018.48 | +23.1% | 482.83 | +927.9% | 17.11 | 31 Jul 2026 |
| Q4 FY26Jan–Mar 2026 | 3,770.59 | +15.8% | 301.32 | 69x | 10.68 | 11 Jun 2026 |
| Q3 FY26Oct–Dec 2025 | 3,900.61 | +15.1% | 403.23 | +15.9% | 14.29 | 30 Jan 2026 |
| Q2 FY26Jul–Sep 2025 | 6,046.87 | +76.1% | 610.43 | +72.2% | 21.63 | 14 Nov 2025 |
| Q1 FY26Apr–Jun 2025 | 3,264.44 | +0.6% | 46.97 | −86.2% | 1.66 | 14 Aug 2025 |
| Q4 FY25Jan–Mar 2025 | 3,256.21 | +6.3% | 4.38 | Turned profit | 0.16 | 23 May 2025 |
| Q3 FY25Oct–Dec 2024 | 3,387.55 | +35.1% | 348.03 | Turned profit | 12.33 | 14 Feb 2025 |
| Q2 FY25Jul–Sep 2024 | 3,433.80 | +7.1% | 354.49 | Turned profit | 12.55 | 15 Nov 2024 |
| Q1 FY25Apr–Jun 2024 | 3,244.19 | −4.6% | 340.24 | +96.5% | 12.06 | 16 Aug 2024 |
| Q4 FY24Jan–Mar 2024 | 3,062.95 | −9.2% | (1,214.27) | Loss widened | (43.18) | 25 May 2024 |
| Q3 FY24Oct–Dec 2023 | 2,506.70 | −27.6% | (330.82) | Turned loss | (12.45) | 15 Feb 2024 |
| Q2 FY24Jul–Sep 2023 | 3,207.38 | −5.0% | (63.55) | Turned loss | (2.90) | 15 Nov 2023 |
| Q1 FY24Apr–Jun 2023 | 3,401.60 | +22.5% | 173.13 | −18.0% | 5.31 | 11 Aug 2023 |
| Q4 FY23Jan–Mar 2023 | 3,373.72 | +11.7% | (403.14) | Turned loss | (15.18) | 22 May 2023 |
| Q3 FY23Oct–Dec 2022 | 3,463.86 | +9.2% | 290.76 | +21.3% | 9.66 | 11 Feb 2023 |
| Q2 FY23Jul–Sep 2022 | 3,375.25 | +7.2% | 278.67 | +1.4% | 9.23 | 13 Nov 2022 |
| Q1 FY23Apr–Jun 2022 | 2,777.29 | −6.3% | 211.11 | −31.1% | 6.82 | 12 Aug 2022 |
| Q4 FY22Jan–Mar 2022 | 3,019.15 | +5.6% | 172.57 | −26.2% | 5.51 | 30 May 2022 |
| Q3 FY22Oct–Dec 2021 | 3,173.41 | +13.9% | 239.75 | −3.4% | 7.86 | 12 Feb 2022 |
| Q2 FY22Jul–Sep 2021 | 3,147.45 | +6.6% | 274.81 | +17.4% | 9.74 | 13 Nov 2021 |
| Q1 FY22Apr–Jun 2021 | 2,964.89 | +26.4% | 306.53 | +20.7% | 10.86 | 14 Aug 2021 |
| Q4 FY21Jan–Mar 2021 | 2,859.90 | +3.3% | 233.87 | +6.2% | 8.29 | 31 May 2021 |
| Q3 FY21Oct–Dec 2020 | 2,786.76 | +1.9% | 248.18 | +30.0% | 8.80 | 13 Feb 2021 |
| Q2 FY21Jul–Sep 2020 | 2,952.48 | +4.9% | 233.99 | −8.4% | 8.29 | 09 Nov 2020 |
| Q1 FY21Apr–Jun 2020 | 2,344.79 | +0.9% | 254.04 | +132.5% | 9.00 | 17 Aug 2020 |
| Q4 FY20Jan–Mar 2020 | 2,767.49 | +8.0% | 220.31 | +36.3% | 7.81 | 27 Jun 2020 |
| Q3 FY20Oct–Dec 2019 | 2,735.56 | +7.1% | 190.84 | +64.0% | 13.52 | 15 Feb 2020 |
| Q2 FY20Jul–Sep 2019 | 2,815.04 | +9.1% | 255.54 | −38.3% | 9.06 | 15 Nov 2019 |
| Q1 FY20Apr–Jun 2019 | 2,322.88 | +7.3% | 109.28 | −53.1% | 3.87 | 14 Aug 2019 |
| Q4 FY19Jan–Mar 2019 | 2,563.47 | — | 161.66 | — | 5.73 | 30 May 2019 |
| Q3 FY19Oct–Dec 2018 | 2,555.05 | — | 116.34 | — | 4.12 | 15 Feb 2019 |
| Q2 FY19Jul–Sep 2018 | 2,581.33 | — | 414.00 | — | 14.67 | 14 Nov 2018 |
| Q1 FY19Apr–Jun 2018 | 2,165.62 | — | 232.99 | — | 8.26 | 11 Aug 2018 |
Standalone results
| Quarter | Revenue | YoY | Net profit | YoY | EPS (₹) | Filed |
|---|---|---|---|---|---|---|
| Q1 FY27Apr–Jun 2026 | 2,434.99 | +1.7% | 735.64 | +122.8% | 26.07 | 31 Jul 2026 |
| Q4 FY26Jan–Mar 2026 | 2,146.58 | +6.8% | (73.90) | Turned loss | (2.62) | 11 Jun 2026 |
| Q3 FY26Oct–Dec 2025 | 2,359.93 | +4.8% | 282.07 | −31.8% | 10.00 | 30 Jan 2026 |
| Q2 FY26Jul–Sep 2025 | 1,538.66 | −41.6% | (739.19) | Turned loss | (26.19) | 14 Nov 2025 |
| Q1 FY26Apr–Jun 2025 | 2,394.93 | +2.8% | 330.23 | −27.2% | 11.70 | 14 Aug 2025 |
| Q4 FY25Jan–Mar 2025 | 2,009.49 | −6.5% | 147.76 | −96.8% | 5.24 | 23 May 2025 |
| Q3 FY25Oct–Dec 2024 | 2,251.28 | +64.9% | 413.80 | Turned profit | 14.66 | 14 Feb 2025 |
| Q2 FY25Jul–Sep 2024 | 2,636.10 | +18.0% | 595.06 | +96.8% | 21.09 | 15 Nov 2024 |
| Q1 FY25Apr–Jun 2024 | 2,329.54 | +8.6% | 453.73 | +67.0% | 16.08 | 16 Aug 2024 |
| Q4 FY24Jan–Mar 2024 | 2,148.22 | +10.8% | 4,613.69 | Turned profit | 163.50 | 25 May 2024 |
| Q3 FY24Oct–Dec 2023 | 1,365.10 | −36.8% | (20.41) | Turned loss | (0.72) | 15 Feb 2024 |
| Q2 FY24Jul–Sep 2023 | 2,233.42 | +1.1% | 302.35 | −28.5% | 10.72 | 15 Nov 2023 |
| Q1 FY24Apr–Jun 2023 | 2,144.38 | +12.2% | 271.66 | −44.9% | 9.63 | 11 Aug 2023 |
| Q4 FY23Jan–Mar 2023 | 1,939.05 | +8.6% | (137.47) | Turned loss | (4.87) | 22 May 2023 |
| Q3 FY23Oct–Dec 2022 | 2,161.47 | +6.3% | 430.50 | −21.5% | 15.26 | 11 Feb 2023 |
| Q2 FY23Jul–Sep 2022 | 2,208.21 | +1.3% | 423.15 | −43.9% | 15.00 | 13 Nov 2022 |
| Q1 FY23Apr–Jun 2022 | 1,911.93 | −10.7% | 492.58 | +0.6% | 17.46 | 12 Aug 2022 |
| Q4 FY22Jan–Mar 2022 | 1,785.54 | −3.5% | 205.60 | −39.8% | 7.29 | 30 May 2022 |
| Q3 FY22Oct–Dec 2021 | 2,033.05 | +3.1% | 548.52 | +24.0% | 19.44 | 12 Feb 2022 |
| Q2 FY22Jul–Sep 2021 | 2,180.87 | +5.8% | 754.26 | +87.2% | 26.73 | 13 Nov 2021 |
| Q1 FY22Apr–Jun 2021 | 2,142.12 | +27.3% | 489.42 | +5.8% | 17.34 | 14 Aug 2021 |
| Q4 FY21Jan–Mar 2021 | 1,850.37 | +15.1% | 341.77 | −2.1% | 12.11 | 31 May 2021 |
| Q3 FY21Oct–Dec 2020 | 1,972.48 | +8.6% | 442.32 | +28.0% | 15.68 | 13 Feb 2021 |
| Q2 FY21Jul–Sep 2020 | 2,062.16 | +15.2% | 402.88 | −6.7% | 14.28 | 09 Nov 2020 |
| Q1 FY21Apr–Jun 2020 | 1,682.92 | +12.3% | 462.48 | +103.0% | 16.39 | 17 Aug 2020 |
| Q4 FY20Jan–Mar 2020 | 1,607.73 | +1.3% | 349.19 | +24.1% | 12.38 | 27 Jun 2020 |
| Q3 FY20Oct–Dec 2019 | 1,816.29 | +11.3% | 345.53 | +76.4% | 24.50 | 15 Feb 2020 |
| Q2 FY20Jul–Sep 2019 | 1,789.82 | +6.6% | 431.99 | −42.2% | 15.31 | 15 Nov 2019 |
| Q1 FY20Apr–Jun 2019 | 1,498.79 | −7.4% | 227.84 | −42.7% | 8.07 | 14 Aug 2019 |
| Q4 FY19Jan–Mar 2019 | 1,587.28 | — | 281.29 | — | 9.97 | 30 May 2019 |
| Q3 FY19Oct–Dec 2018 | 1,632.04 | — | 195.87 | — | 6.94 | 15 Feb 2019 |
| Q2 FY19Jul–Sep 2018 | 1,679.71 | — | 747.56 | — | 26.49 | 14 Nov 2018 |
| Q1 FY19Apr–Jun 2018 | 1,618.41 | — | 397.39 | — | 14.08 | 11 Aug 2018 |
66 filings on record for this company.